These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 21968371)

  • 1. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.
    Kim WY; Young Suh G; Huh JW; Kim SH; Kim MJ; Kim YS; Kim HR; Ryu YJ; Han MS; Ko YG; Chon GR; Lee KH; Choi SH; Hong SB;
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5703-9. PubMed ID: 21968371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
    Beigel JH; Bao Y; Beeler J; Manosuthi W; Slandzicki A; Dar SM; Panuto J; Beasley RL; Perez-Patrigeon S; Suwanpimolkul G; Losso MH; McClure N; Bozzolo DR; Myers C; Holley HP; Hoopes J; Lane HC; Hughes MD; Davey RT;
    Lancet Infect Dis; 2017 Dec; 17(12):1255-1265. PubMed ID: 28958678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.
    Nguyen JT; Smee DF; Barnard DL; Julander JG; Gross M; de Jong MD; Went GT
    PLoS One; 2012; 7(1):e31006. PubMed ID: 22292088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza A (H1N1) infection.
    Kang SJ; Park KH; Kee SJ; Shin JH; Jung SI; Kwon YS; Jang HC
    Jpn J Infect Dis; 2013; 66(5):425-7. PubMed ID: 24047743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.
    Seo S; Englund JA; Nguyen JT; Pukrittayakamee S; Lindegardh N; Tarning J; Tambyah PA; Renaud C; Went GT; de Jong MD; Boeckh MJ
    Antivir Ther; 2013; 18(3):377-86. PubMed ID: 23264438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
    Nguyen JT; Hoopes JD; Le MH; Smee DF; Patick AK; Faix DJ; Blair PJ; de Jong MD; Prichard MN; Went GT
    PLoS One; 2010 Feb; 5(2):e9332. PubMed ID: 20179772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.
    Petersen E; Keld DB; Ellermann-Eriksen S; Gubbels S; Ilkjær S; Jensen-Fangel S; Lindskov C
    Scand J Infect Dis; 2011 Jul; 43(6-7):495-503. PubMed ID: 21309638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection.
    Viasus D; Paño-Pardo JR; Pachón J; Riera M; López-Medrano F; Payeras A; Fariñas MC; Moreno A; Rodríguez-Baño J; Oteo JA; Ortega L; Torre-Cisneros J; Segura F; Carratalà J;
    Chest; 2011 Oct; 140(4):1025-1032. PubMed ID: 21415133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
    Smee DF; Hurst BL; Wong MH; Bailey KW; Morrey JD
    Antimicrob Agents Chemother; 2009 May; 53(5):2120-8. PubMed ID: 19273672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
    Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
    Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses.
    Smee DF; Wong MH; Bailey KW; Sidwell RW
    Antivir Chem Chemother; 2006; 17(4):185-92. PubMed ID: 17066897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus.
    Hoopes JD; Driebe EM; Kelley E; Engelthaler DM; Keim PS; Perelson AS; Rong L; Went GT; Nguyen JT
    PLoS One; 2011; 6(12):e29778. PubMed ID: 22220216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.
    Masihi KN; Schweiger B; Finsterbusch T; Hengel H
    J Chemother; 2007 Jun; 19(3):295-303. PubMed ID: 17594925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A.
    Rodríguez A; Díaz E; Martín-Loeches I; Sandiumenge A; Canadell L; Díaz JJ; Figueira JC; Marques A; Alvarez-Lerma F; Vallés J; Baladín B; García-López F; Suberviola B; Zaragoza R; Trefler S; Bonastre J; Blanquer J; Rello J;
    J Antimicrob Chemother; 2011 May; 66(5):1140-9. PubMed ID: 21385717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oseltamivir- and amantadine-resistant influenza virus A (H1N1).
    Cheng PK; To AP; Leung TW; Leung PC; Lee CW; Lim WW
    Emerg Infect Dis; 2010 Jan; 16(1):155-6. PubMed ID: 20031069
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current anti-influenza virus chemotherapy].
    Yoshioka D; Tokimatsu I; Ishii H; Kadota J
    Nihon Rinsho; 2010 Sep; 68(9):1679-84. PubMed ID: 20845747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days.
    Ryoo SM; Kim WY; Sohn CH; Seo DW; Oh BJ; Lee JH; Lee YS; Lim KS
    Influenza Other Respir Viruses; 2013 Sep; 7(5):833-7. PubMed ID: 23279949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza.
    Yoo JW; Choi SH; Huh JW; Lim CM; Koh Y; Hong SB
    J Med Virol; 2015 Oct; 87(10):1649-55. PubMed ID: 25946636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study.
    Hiba V; Chowers M; Levi-Vinograd I; Rubinovitch B; Leibovici L; Paul M
    J Antimicrob Chemother; 2011 May; 66(5):1150-5. PubMed ID: 21393197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.